---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-058240"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:05:03.439517+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx Q3 revenue $98.1M (+8% YoY); reaffirms FY2023 guidance $425-450M

## Summary
- Total revenue $98.1M, up 8% YoY; Crysvita $74.9M, Dojolvi $16.6M.
- Net loss $159.6M ($2.23/share), improved from $245.1M ($3.50/share) in Q3 2022.
- Cash $524.2M at Sept 30; net $326.5M from October offering.
- FY2023 guidance reaffirmed: total revenue $425-450M, Crysvita $325-340M, Dojolvi $65-75M.
- Clinical: UX143 (OI) 67% fracture rate reduction; GTX-102 (Angelman) improvements; UX701 (Wilson) patients tapering.

## SEC filing metadata
- accession: 0000950170-23-058240
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000095017023058240/0000950170-23-058240-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000095017023058240/rare-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-058240
- JSON: https://secwatch.observer/filing/0000950170-23-058240.json
- Plain text: https://secwatch.observer/filing/0000950170-23-058240.txt

## Key facts
- Earnings Releases
  Ultragenyx Pharmaceutical Inc. reported the quarter ended September 30, 2023 results: revenue $98.1 million. Guidance reaffirmed.
  - Period: the quarter ended September 30, 2023
  - Revenue: $98.1 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Higa ir@ultragenyx.com Media Jeff Blake media@ultragenyx.com Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update Third quarter 2023 total revenue of $98.1 million, Crysvita® revenue of $74.9 million and Dojolvi® revenue of $ 16.6 million Reaffirmed 2023 expected total revenue guidance between $425 million to $450 million, Crysvita revenue
  evidence_url: https://www.sec.gov/Archives/edgar/data/1515673/000095017023058240/0000950170-23-058240-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.